While GLP-1 agonists have garnered significant attention, GLP-1 inhibitors provide complementary insights into pathway inhibition
We offer a range of assays and in vivo models to assess the therapeutic potential of novel drugs to treat obesity: Rodent models DIO and weight gain in mice and rats Most commercially available genetic models Drug-induced weight gain (Olanzapine, Pioglitazone) Acute Studies Food intake assessment (fed, fasted, dark-phase induced, palatable diet models) Behavioural profiling Gastric emptying Glucose and insulin tolerance (OGTT, IPGTT, IVGTT, ITT) Energy expenditure (by indirect calorimetry) Chronic Studies Chronic dosing or subcutaneous infusion (up to 12 weeks) Body weight, food and water intake Pair-feeding and weight-matching paradigms Body composition (validated scanning techniques or full chemical carcass analysis) Plasma, urine and liver metabolic parameters and biomarkers Glucose and insulin tolerance (OGTT, IPGTT, IVGTT, ITT) Energy expenditure (by indirect calorimetry) Faecal energy content We offer full experimental design consultation, tailoring your study to your exact requirements
That is approaching tirzepatide territory, particularly considering the shorter trial duration
Is Hims like Ozempic
In fact, Wegovy has been shown to help improve blood sugar levels as part of a comprehensive weight management programme.
